MedTrace Logo

Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection

NCT03834376 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2020-10-28

No results posted yet for this study

Summary

The purpose of this program is to provide pre-approval access to pimodivir for the treatment of a patient(s) with H7N9 influenza A infection. Pre-approval access pertains to provision for therapeutic use of an investigational product prior to its marketing authorization. Such access may be considered for eligible patients with serious/life-threatening diseases or conditions, where alternative treatments do not exist or have been exhausted.

Conditions

  • H7N9 Subtype of Influenza A Virus

Interventions

DRUG

Pimodivir

Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram \[mg\]) over a time period of 5 days.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834376 on ClinicalTrials.gov